17 completed, 6 recruiting, 3 terminated, 2 unknown. 9 Phase 2, 4 Not applicable, 2 Early Phase 1, 2 Phase 1, 1 Phase 3.
Follow Leukoencephalopathy, Progressive Multifocal: new trials by email Literature Review of Leukoencephalopathy, Progressive Multifocal trials Research Report on Leukoencephalopathy, Progressive Multifocal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study Brincidofovir - Progressive Multifocal Leukoencephalopathy | Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2026-06-05 | 2026-07-22 |
| Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia Ozanimod - Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy | Recruiting | Bristol-Myers Squibb | 15 | 2026-06-04 | 2026-07-29 | |
| T-cell Therapy in Patients With PML Application of T-lymphocytes - Progressive Multifocal Leucoencephalopathy (PML) | Phase 2 | Recruiting | Hannover Medical School | 23 | 2026-02-06 | 2026-10-15 |
| Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection - Progressive Multifocal Leukoencephalopathy | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2024-04-01 | 2024-02-26 |
| Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy 89 Zr-Df-crefmirlimab - Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis | Phase 1 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 2023-10-19 | 2026-06-05 |
| Observational Cohort Study of Chronic Viral Infection in the Central Nervous System Immune Checkpoint Inhibitors - Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors | Recruiting | Peking Union Medical College Hospital | 66 | 2023-02-20 | 2026-04-06 | |
| A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML CE-VST01-JC - Progressive Multifocal Leukoencephalopathy | Phase 2 | Unknown | Cellevolve Bio Inc | 60 | 2023-02-01 | 2022-09-16 |
| NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy NT-I7 - Progressive Multifocal Leukoencephalopathy | Early Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 12 | 2021-05-05 | 2025-11-18 |
| Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy Collection of blood and urine, Spinal tap, Brain MRI - Progressive Multifocal Leukoencephalopathy | Not applicable | Completed | University Hospital, Toulouse | 22 | 2021-02-23 | 2025-12-31 |
| Treatment of PD-1 Inhibitor in AIDS-associated PML Pembrolizumab - Progressive Multifocal Leukoencephalopathy, AIDS | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 10 | 2019-08-20 | 2019-09-20 |
| TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants Natalizumab - Multiple Sclerosis | Completed | Biogen | 675 | 2019-01-01 | 2025-05-13 | |
| Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries Tysabri - Progressive Multifocal Leukoencephalopathy | Completed | Biogen | 80327 | 2017-06-01 | 2024-03-19 | |
| Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells PyVST - Progressive Multifocal Leukoencephalopathy | Early Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 60 | 2016-03-28 | 2026-07-17 |
| Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis biological samples and clinical data - Multiple Sclerosis | Completed | University Hospital, Toulouse | 307 | 2013-11-19 | 2020-08-25 | |
| Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) Progressive Multifocal Leukoencephalopathy | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 700 | 2012-11-08 | 2026-08-31 | |
| JC Virus Reactivation in Multiple Sclerosis Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis | Completed | Beth Israel Deaconess Medical Center | 50 | 2010-10-01 | 2016-01-29 | |
| Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy Progressive Multifocal Leukoencephalopathy | Terminated | Biogen | 24 | 2010-10-01 | 2015-01-19 | |
| Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Methylprednisolone, Prednisolone - Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal | Phase 4 | Terminated | Biogen | 3 | 2010-09-01 | 2014-09-05 |
| Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) mefloquine - Progressive Multifocal Leukoencephalopathy | Phase 1 / Phase 2 | Terminated | Biogen | 37 | 2009-01-01 | 2014-07-31 |
| Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy? Measure of overall survival - AIDS, Progressive Multifocal Leucoencephalopathy (PML) | Completed | Fondation Ophtalmologique Adolphe de Rothschild | 34 | 2008-01-01 | 2019-05-31 |
Showing 20 of 29. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (7) · HIV Infections (6) · Multiple Sclerosis (6) · Immune Reconstitution Inflammatory Syndrome (3) · Central Nervous System Diseases (2) · AIDS-Related Opportunistic Infections (1) · Encephalitis (1)
Brain Diseases (29) · Central Nervous System Infections (29) · Central Nervous System Viral Diseases (29) · DNA Virus Infections (29) · Demyelinating Diseases (29) · Encephalitis, Viral (29) · Infections (29) · Infectious Encephalitis (29) · Leukoencephalopathies (29) · Nervous System Diseases (29) · Neuroinflammatory Diseases (29) · Polyomavirus Infections (29) · Slow Virus Diseases (29) · Virus Diseases (29) · Encephalitis (28)
Didanosine (2) · Immune Checkpoint Inhibitors (2) · Natalizumab (2) · Zidovudine (2) · pembrolizumab (2) · Cidofovir (1) · Cytarabine (1) · Enfuvirtide (1) · Filgrastim (1) · Injections (1) · Interferon alpha-2 (1) · Mefloquine (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Prednisolone (1)
Biogen (5) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · Beth Israel Deaconess Medical Center (2) · Bristol-Myers Squibb (2) · Fondation Ophtalmologique Adolphe de Rothschild (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University Hospital, Toulouse (2) · Assistance Publique - Hôpitaux de Paris (1) · Cellevolve Bio Inc (1) · First Affiliated Hospital of Zhejiang University (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Hannover Medical School (1) · Peking Union Medical College Hospital (1) · Scientific Institute San Raffaele (1) · SmithKline Beecham (1)
United States (17) · Germany (5) · France (4) · China (2) · Italy (2) · Spain (2) · Brazil (1) · Czechia (1)
Irene CM Cortese, M.D. (4) · Barker DE (1) · Biao Zhu, PhD (1) · Chen S Tan, MD (1) · Daniel S Reich, M.D. (1) · David Brassat, MD,PHD (1) · Dominique Costagliola (1) · Hall C (1) · Igor J Koralnik, MD (1) · Jacques Gasnault, MD (1) · Marra CM (1) · Paola Cinque, MD, PhD (1)
PMID 21738597, PMID 23733308, PMID 24687904, PMID 34302788
2005 (1), 2023 (1)